Berlex Betapace
Executive Summary
FDA's Cardio-Renal Drugs Advisory Committee will review the class III anti-arrhythmic agent sotalol (NDA 19-865) for prevention of the recurrence of chronic or paroxysmal atrial fibrillation or flutter on April 29 beginning at 9 a.m. Betapace is approved for documented ventricular arrhythmia. The committee will meet to discuss anti-arrhythmia trials in patients with implanted ventricular defibrillators on April 30 starting at 8:30 a.m. The meeting will be held at the National Institutes of Health Masur Auditorium in Bethesda, Md
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth